MEDIPOST has ended the license agreement with Dong-A ST which has been the domestic distributor of MEDIPOST’s stem cell drug, ‘CARTISTEM^®’ and will begin the sales of ‘CARTISTEM^®’ on its own.

Managing the research, development, manufacturing, sales and marketing of the drug, MEDIPOST plans to expand its position in the stem cell treatment market.

Through this change, MEDIPOST will also be able to management the product and its shipment more efficiently and focus on marketing and meeting consumer needs using its own sales strategies.

MEDIPOST established an exclusive department in charge of managing the sales of ‘CARTISTEM^®’ and hired outside experts as well.